GlassScriptPhysician profile
Edward Y Chan
NPI 1033155213
$10,423.29
in general payments reported to CMS, 2019-2025
31 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,358 · 2020: $82.45 · 2021: $625 · 2022: $1,170 · 2023: $1,540 · 2024: $1,460 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,917 · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,916.74 |
| Education | $270.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,072.64 | 2019-2025 | Tagrisso, Enhertu, Calquence |
| Bayer Healthcare Pharmaceuticals INC. | $1,737.95 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $660.66 | 2019-2025 | Opdivo, Reblozyl, Augtyro |
| Takeda Pharmaceuticals U.S.A., INC. | $357.44 | 2020-2023 | Alunbrig |
| Merck Sharp & Dohme LLC | $343.55 | 2022-2025 | Keytruda, Lynparza |
| Lilly USA, LLC | $312.44 | 2021-2025 | Jaypirca, Verzenio |
| Janssen Pharmaceuticals, INC | $297.20 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $280.86 | 2021-2024 | Zejula, Ojjaara, Jemperli |
| Gilead Sciences, INC. | $275.50 | 2019-2024 | Vemlidy |
| Regeneron Healthcare Solutions, INC. | $240.96 | 2022-2025 | Libtayo |
| Epizyme, INC. | $207.95 | 2021 | |
| Janssen Biotech, INC. | $178.07 | 2023-2025 | Balversa, Akeega, Erleada |
| Rigel Pharmaceuticals, INC. | $172.06 | 2022-2024 | Rezlidhia, Tavalisse |
| Agios Pharmaceuticals, INC. | $131.85 | 2024-2025 | Pyrukynd |
| Eisai INC. | $122.98 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.85 | 2022 | |
| Genzyme Corporation | $118.38 | 2022 | |
| Coherus Oncology, INC. | $114.91 | 2024-2025 | Loqtorzi |
| Amgen INC. | $111.90 | 2022-2024 | Vectibix, Parsabiv, Aranesp |
| Astellas Pharma US INC | $107.88 | 2023-2025 | Vyloy |
| Celgene Corporation | $76.90 | 2024-2025 | Opdivo, Pomalyst |
| Dynavax Technologies Corporation | $66.90 | 2024 | Heplisav-B |
| Travere Therapeutics, INC. | $62.28 | 2025 | |
| Array Biopharma INC | $52.06 | 2025 | Xalkori, Lorbrena, Braftovi |
| Novartis Pharmaceuticals Corporation | $50.42 | 2024-2025 | |
| Novocure INC. | $40.91 | 2024-2025 | Optune Lua (Novottf-200t) |
| Geron Corporation | $33.19 | 2024 | Rytelo |
| Morphosys, US INC. | $24.76 | 2022 | |
| Exact Sciences Corporation | $22.14 | 2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $15.00 | 2022 | |
| Dova Pharmaceuticals | $14.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.